Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA RECALLS & COURT ACTIONS: June 23, 1993

Executive Summary

CLASS II - NEOMYCIN SULFATE TABLETS, 500 MG In bottles of 100, a Rx antibiotic. Recall number: D-282-3. All lots. Manufacturer: Eon Labs Manufacturing, Inc., Laurelton, New York. Recalled by: Manufacturer, by telephone and by letter June 11, 1993. Firm-initiated recall ongoing. Distribution: Nationwide; 21,000 bottles were distributed. Reason: Discrepancies in manufacturing procedures. CLASS III - (a) DONNAZYME TABLETS; (b) ENTOZYME TABLETS (a) In 100 tablet bottles, Pancreatin, USP equivalent 500 mg; (b) in 100 tablet bottles, Pancreatin, USP equivalent 300 mg. Recall number: D-280/281-3. All lots. Manufacturer: Whitehall-Robins, Richmond, Virginia. Recalled by: Manufacturer, by letter May 25, 1993. Firm-initiated recall ongoing. Distribution: Nationwide, Puerto Rico, Canada; undetermined quantity. Reason: Potency not assured through expiration date.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS022845

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel